CLAIMS

1. Use of a polypeptide in the manufacture of a medicament for the treatment of cancer, wherein the treatment involves stimulating the production of anti-intracellular oncoprotein antibodies in a subject in need thereof, the polypeptide comprising a fragment of an intracellular oncoprotein having between 10 and 150 amino acids, preferably between 10 and 100 amino acids, wherein the intracellular oncoprotein is PRL3.

2. Use according to claim 1 wherein the fragment comprises an oncogenic mutation.

3. Use according to claim 1 or claim 2 wherein the polypeptide comprises a plurality of fragments.

4. Use according to claim 3 wherein the polypeptide comprises a plurality of fragments of the same oncoprotein.

5. Use according to claim 4 wherein the polypeptide comprises a plurality of fragments from two or more oncoproteins.

6. Use according to any one of the preceding claims, wherein the treatment of cancer is for reducing cancer metastasis.

7. Use to any one of the preceding claims wherein the patient has a primary cancer that expresses the intracellular oncoprotein.

8. Use of a fragment of between 10 and 150 amino acids of an intracellular oncoprotein in the manufacture of a medicament for treating cancer metastasis in a patient with cancer, wherein the intracellular oncoprotein was identified to be specific to the patient's cancer, wherein the intracellular oncoprotein is PRL3.

9. Use of a fragment of an intracellular oncoprotein comprising between 10 and 150 amino acids in length in the manufacture of a medicament for treating cancer in a person, wherein the person was determined as suffering from, or likely to develop, a cancer associated with the intracellular oncoprotein before administration of the fragment or peptide to that person, wherein the intracellular oncoprotein is PRL3.

10. The use of claim 8 or claim 9 wherein the fragment comprises an oncogenic mutation.

11. The use of any one of claims 8 to 10 wherein the patient is administered a plurality of oncoprotein fragments.

12. The use of claim 11 wherein the plurality of oncoprotein fragments are combined into one peptide, each optionally linked by a peptide linker.

13. The use of any one of claims 8 to 12 wherein the patient is induced to produce antibodies against the peptide.

14. The use of any one of claims 9 to 13 wherein the person is to be administered with the intracellular oncoprotein fragment or peptide before he/she develops the cancer.

15. The use of any one of claims 8 to 14 wherein the person is to be administered with a further dose of the intracellular oncoprotein fragment or peptide.

16. The use of any one of claims 9 to 15 wherein the person has been identified as being likely to suffer from a cancer associated with an intracellular oncoprotein by assessing the prevalence of the cancer in family members.

17. The use according to any one of the preceding claims, in which the intracellular oncoprotein comprises a cytoplasmic or nuclear oncoprotein.

18. The use according to any preceding claim, in which the cancer is associated with or caused by over-expression of the intracellular oncoprotein.

19. The use according to any preceding claim, in which the cancer is selected from the group consisting of: breast cancer, hepatocellular cancer, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical cancer, anal cancer, bladder cancer, blood cancer, bone cancer, brain tumor, cancer of the female genital system, cancer of the male genital system, central nervous system lymphoma, cervical cancer, childhood rhabdomyosarcoma, childhood sarcoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), colon and rectal cancer, colon cancer, endometrial cancer, endometrial sarcoma, esophageal cancer, eye cancer, gallbladder cancer, gastric cancer, gastrointestinal tract cancer, hairy cell leukemia, head and neck cancer, Hodgkin's disease,